Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:ANIP NYSE:ANVS NASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$17.31+0.6%$19.01$10.21▼$25.67$4.11B0.432.58 million shs1.82 million shsANIPANI Pharmaceuticals$66.77-0.2%$63.16$52.50▼$77.00$1.45B0.57279,070 shs265,690 shsANVSAnnovis Bio$2.86+7.5%$2.55$1.11▼$11.29$51.83M1.57333,858 shs519,853 shsRYTMRhythm Pharmaceuticals$87.27-0.6%$68.97$40.61▼$94.80$5.59B2.26991,858 shs388,632 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+0.88%-2.77%-3.75%-22.97%+25.00%ANIPANI Pharmaceuticals+0.84%+0.45%+1.32%-3.93%+3.35%ANVSAnnovis Bio+1.07%-5.45%-0.19%+61.16%-75.23%RYTMRhythm Pharmaceuticals-0.01%-3.97%+41.33%+39.45%+76.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics3.7893 of 5 stars3.71.00.00.02.42.53.1ANIPANI Pharmaceuticals3.8559 of 5 stars2.51.00.03.33.23.31.3ANVSAnnovis Bio2.2666 of 5 stars3.51.00.00.02.71.70.6RYTMRhythm Pharmaceuticals3.1313 of 5 stars2.51.00.04.32.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6759.83% UpsideANIPANI Pharmaceuticals 3.00Buy$78.8818.13% UpsideANVSAnnovis Bio 3.00Buy$18.00529.59% UpsideRYTMRhythm Pharmaceuticals 3.07Buy$91.935.34% UpsideCurrent Analyst Ratings BreakdownLatest ANIP, ADMA, ANVS, and RYTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025RYTMRhythm PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$92.00 ➝ $105.007/10/2025RYTMRhythm PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/10/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$84.007/10/2025RYTMRhythm PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$76.00 ➝ $110.007/10/2025RYTMRhythm PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$73.00 ➝ $95.007/10/2025RYTMRhythm PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$91.00 ➝ $129.007/10/2025RYTMRhythm PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$97.007/9/2025RYTMRhythm PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$95.007/9/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $95.007/7/2025RYTMRhythm PharmaceuticalsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/7/2025RYTMRhythm PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Outperform$88.00(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M9.69$0.54 per share31.78$1.48 per share11.70ANIPANI Pharmaceuticals$614.38M2.35$7.58 per share8.81$19.11 per share3.49ANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/ARYTMRhythm Pharmaceuticals$130.13M42.67N/AN/A$0.35 per share249.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8530.7125.09N/A45.01%47.16%30.51%8/6/2025 (Estimated)ANIPANI Pharmaceuticals-$18.52M-$1.2714.9315.86N/A-3.12%21.35%7.52%8/5/2025 (Estimated)ANVSAnnovis Bio-$24.59M-$2.160.00N/AN/AN/A-300.56%-193.50%8/13/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$2.810.00N/AN/A-123.26%-739.62%-44.27%8/5/2025 (Estimated)Latest ANIP, ADMA, ANVS, and RYTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ADMAADMA Biologics$0.14N/AN/AN/AN/AN/A8/13/2025Q2 2025ANVSAnnovis Bio-$0.36N/AN/AN/AN/AN/A8/5/2025Q2 2025ANIPANI Pharmaceuticals$1.49N/AN/AN/A$187.18 millionN/A8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.64N/AN/AN/A$43.72 millionN/A5/13/2025Q1 2025ANVSAnnovis Bio-$0.47-$0.32+$0.15-$0.32N/AN/A5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 million5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.226.583.36ANIPANI Pharmaceuticals1.462.661.98ANVSAnnovis BioN/A10.6810.68RYTMRhythm PharmaceuticalsN/A3.303.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%ANIPANI Pharmaceuticals76.05%ANVSAnnovis Bio15.83%RYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.50%ANIPANI Pharmaceuticals11.10%ANVSAnnovis Bio20.80%RYTMRhythm Pharmaceuticals6.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million230.38 millionOptionableANIPANI Pharmaceuticals60021.66 million19.26 millionOptionableANVSAnnovis Bio319.49 million15.43 millionOptionableRYTMRhythm Pharmaceuticals14063.62 million59.74 millionOptionableANIP, ADMA, ANVS, and RYTM HeadlinesRecent News About These CompaniesRhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025July 22 at 4:01 PM | globenewswire.comRhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $105.00July 21 at 4:03 AM | americanbankingnews.comRhythm Pharmaceuticals (NASDAQ:RYTM) Cut to "Sell" at Wall Street ZenJuly 21 at 3:11 AM | americanbankingnews.comRhythm Pharmaceuticals (NASDAQ:RYTM) Lowered to Sell Rating by Wall Street ZenJuly 19, 2025 | marketbeat.comRhythm Pharmaceuticals CFO Sells 42,120 SharesJuly 18, 2025 | msn.comRhythm Pharmaceuticals (NASDAQ:RYTM) Given New $105.00 Price Target at Canaccord Genuity GroupJuly 18, 2025 | marketbeat.comQ2 Earnings Estimate for RYTM Issued By Leerink PartnrsJuly 16, 2025 | marketbeat.comAnalysts Set Expectations for RYTM Q4 EarningsJuly 15, 2025 | marketbeat.comQ2 EPS Estimate for Rhythm Pharmaceuticals Lifted by AnalystJuly 15, 2025 | americanbankingnews.comLeo Wealth LLC Purchases New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)July 14, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Sells $3,389,817.60 in StockJuly 14, 2025 | americanbankingnews.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 15,572 Shares of StockJuly 14, 2025 | americanbankingnews.comLeerink Partnrs Issues Optimistic Outlook for RYTM EarningsJuly 14, 2025 | marketbeat.comAlps Advisors Inc. Has $2.45 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)July 13, 2025 | marketbeat.comRhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025July 12, 2025 | globenewswire.comRhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It ... - NasdaqJuly 12, 2025 | nasdaq.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 3,817 Shares of StockJuly 12, 2025 | insidertrades.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German Sells 3,817 SharesJuly 11, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $619,828.82 in StockJuly 11, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Pamela J. Cramer Sells 15,572 SharesJuly 11, 2025 | marketbeat.comHunter C. Smith Sells 42,120 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockJuly 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANIP, ADMA, ANVS, and RYTM Company DescriptionsADMA Biologics NASDAQ:ADMA$17.31 +0.11 (+0.64%) Closing price 04:00 PM EasternExtended Trading$17.15 -0.16 (-0.92%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.ANI Pharmaceuticals NASDAQ:ANIP$66.77 -0.13 (-0.19%) Closing price 04:00 PM EasternExtended Trading$67.10 +0.33 (+0.49%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Annovis Bio NYSE:ANVS$2.86 +0.20 (+7.48%) Closing price 03:59 PM EasternExtended Trading$2.84 -0.02 (-0.66%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Rhythm Pharmaceuticals NASDAQ:RYTM$87.27 -0.54 (-0.61%) Closing price 04:00 PM EasternExtended Trading$87.24 -0.02 (-0.03%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.